Blodgett Wealth Advisors LLC Reduces Holdings in Pfizer Inc. (NYSE:PFE)

Blodgett Wealth Advisors LLC decreased its position in shares of Pfizer Inc. (NYSE:PFE) by 55.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 17,196 shares of the biopharmaceutical company’s stock after selling 21,697 shares during the period. Blodgett Wealth Advisors LLC’s holdings in Pfizer were worth $495,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Briaud Financial Planning Inc bought a new stake in shares of Pfizer during the 3rd quarter valued at about $30,000. GoalVest Advisory LLC grew its position in shares of Pfizer by 304.9% during the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 811 shares during the last quarter. Mizuho Securities Co. Ltd. bought a new stake in shares of Pfizer during the 3rd quarter valued at about $34,000. VisionPoint Advisory Group LLC grew its position in shares of Pfizer by 52,350.0% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 1,047 shares during the last quarter. Finally, Tennessee Valley Asset Management Partners bought a new stake in shares of Pfizer during the 4th quarter valued at about $36,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on PFE. TD Cowen downgraded shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective for the company. in a research report on Thursday, January 4th. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research note on Monday, April 15th. Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Finally, Guggenheim began coverage on shares of Pfizer in a research note on Friday, February 23rd. They set a “buy” rating and a $36.00 target price for the company. Eleven investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $36.33.

Pfizer Price Performance

Shares of NYSE:PFE traded up $0.12 during trading on Friday, reaching $25.38. The company had a trading volume of 46,479,102 shares, compared to its average volume of 42,011,723. Pfizer Inc. has a twelve month low of $25.20 and a twelve month high of $40.37. The firm has a market capitalization of $143.72 billion, a PE ratio of 70.50, a price-to-earnings-growth ratio of 1.18 and a beta of 0.61. The firm’s fifty day moving average is $26.96 and its 200 day moving average is $28.42. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, beating the consensus estimate of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The business had revenue of $14.25 billion during the quarter, compared to analyst estimates of $14.37 billion. During the same period in the prior year, the business earned $1.14 earnings per share. The business’s quarterly revenue was down 41.3% on a year-over-year basis. On average, equities analysts forecast that Pfizer Inc. will post 2.24 EPS for the current year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 14th. Investors of record on Friday, May 10th will be paid a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a yield of 6.62%. The ex-dividend date of this dividend is Thursday, May 9th. Pfizer’s dividend payout ratio is presently 466.67%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.